Oruka Therapeutics, Inc. Amortization
Oruka Therapeutics, Inc. (ORKA) reported Amortization of $329.00 thousand for the 12-month period ending 2017-12-31, per its 10-K filed 2019-02-27.
Discontinued › Cash Flow › Operating Activities
us-gaap:AdjustmentForAmortization · last filed 2019-02-27
- Oruka Therapeutics, Inc. amortization for the quarter ending 2017-12-31 was $60.00K, a 32.58% decline year-over-year.
- Oruka Therapeutics, Inc. amortization for the quarter ending 2017-09-30 was $90.00K, a 0.00% change year-over-year.
- Oruka Therapeutics, Inc. amortization for the quarter ending 2017-06-30 was $89.00K, a 48.33% increase year-over-year.
- Oruka Therapeutics, Inc. amortization for the quarter ending 2017-03-31 was $90.00K, a 57.89% increase year-over-year.
- Oruka Therapeutics, Inc. amortization for fiscal 2017 was $329.00K, a 11.15% increase from fiscal 2016.
- Oruka Therapeutics, Inc. amortization for fiscal 2016 was $296.00K, a 56.61% increase from fiscal 2015.
- Oruka Therapeutics, Inc. amortization for fiscal 2015 was $189.00K.
| Period end | Amortization 3 month | Amortization 6 month | Amortization 9 month | Amortization 12 month |
|---|---|---|---|---|
| 2017-12-31 | $60.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $150.00K derived: sum of 2 quarters · filed 2019-02-27 | $239.00K derived: sum of 3 quarters · filed 2019-02-27 | $329.00K 10-K · filed 2019-02-27 |
| 2017-09-30 | $90.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | $179.00K derived: sum of 2 quarters · filed 2018-11-14 | $269.00K 10-Q · filed 2018-11-14 | $358.00K derived: sum of 4 quarters · filed 2018-11-14 |
| 2017-06-30 | $89.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $179.00K 10-Q · filed 2018-08-09 | $268.00K derived: sum of 3 quarters · filed 2018-08-09 | $358.00K derived: sum of 4 quarters · filed 2018-08-09 |
| 2017-03-31 | $90.00K 10-Q · filed 2018-05-08 | $179.00K derived: sum of 2 quarters · filed 2018-05-08 | $269.00K derived: sum of 3 quarters · filed 2018-05-08 | $329.00K derived: sum of 4 quarters · filed 2018-05-08 |
| 2016-12-31 | $89.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-22 | $179.00K derived: sum of 2 quarters · filed 2018-03-22 | $239.00K derived: sum of 3 quarters · filed 2018-03-22 | $296.00K 10-K · filed 2018-03-22 |
| 2016-09-30 | $90.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $150.00K derived: sum of 2 quarters · filed 2017-11-09 | $207.00K 10-Q · filed 2017-11-09 | $263.00K derived: sum of 4 quarters · filed 2017-11-09 |
| 2016-06-30 | $60.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $117.00K 10-Q · filed 2017-08-03 | $173.00K derived: sum of 3 quarters · filed 2017-08-03 | $228.00K derived: sum of 4 quarters · filed 2017-08-03 |
| 2016-03-31 | $57.00K 10-Q · filed 2017-05-15 | $113.00K derived: sum of 2 quarters · filed 2017-05-15 | $168.00K derived: sum of 3 quarters · filed 2017-05-15 | $215.00K derived: sum of 4 quarters · filed 2017-05-15 |
| 2015-12-31 | $56.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-21 | $111.00K derived: sum of 2 quarters · filed 2017-03-21 | $158.00K derived: sum of 3 quarters · filed 2017-03-21 | $189.00K 10-K · filed 2017-03-21 |
| 2015-09-30 | $55.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14 | $102.00K derived: sum of 2 quarters · filed 2016-11-14 | $133.00K 10-Q · filed 2016-11-14 | |
| 2015-06-30 | $47.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $78.00K 10-Q · filed 2016-08-09 | ||
| 2015-03-31 | $31.00K 10-Q · filed 2016-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Veradermics, Inc (MANE) | United States | $4.839B |